APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell Immunotherapy Platform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cell Immunotherapy Platform Market Outlook and Growth Opportunities 2026

5 June 2026197 pages

Choose your research edition.

Industry ResearchCell Immunotherapy Platform Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell Immunotherapy Platform Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Cell Immunotherapy Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell Immunotherapy Platform Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell Immunotherapy Platform Market Analysis and Forecast 2026-2032189 pages · $4,950 USD

Market perspective

The global Cell Immunotherapy Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cell Immunotherapy Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell Immunotherapy Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell Immunotherapy Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cell Immunotherapy Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cell Immunotherapy Platform market include Kite Pharma, Novartis, Bristol Myers Squibb, Gilead Sciences, Bluebird Bio, Celyad Oncology, Autolus Therapeutics, Legend Biotech and Celltrion, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cell Immunotherapy Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell Immunotherapy Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell Immunotherapy Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell Immunotherapy Platform market.

Cell Immunotherapy Platform Segment by Company

Kite Pharma

Novartis

Bristol Myers Squibb

Gilead Sciences

Bluebird Bio

Celyad Oncology

Autolus Therapeutics

Legend Biotech

Celltrion

Cell Immunotherapy Platform Segment by Type

Autologous Immune Cell Therapy

Allogeneic Immune Cell Therapy

Cell Immunotherapy Platform Segment by Application

Immunotherapy Industry

Biopharmaceutical Industry

Others

Cell Immunotherapy Platform Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cell Immunotherapy Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cell Immunotherapy Platform key companies, revenue, market share, and recent developments.

3. To split the Cell Immunotherapy Platform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cell Immunotherapy Platform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cell Immunotherapy Platform significant trends, drivers, influence factors in global and regions.

6. To analyze Cell Immunotherapy Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Immunotherapy Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell Immunotherapy Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Immunotherapy Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell Immunotherapy Platform industry.

Chapter 3: Detailed analysis of Cell Immunotherapy Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cell Immunotherapy Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cell Immunotherapy Platform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cell Immunotherapy Platform Industry Trends Table 2. Cell Immunotherapy Platform Industry Drivers Table 3. Cell Immunotherapy Platform Industry Opportunities and Challenges Table 4. Cell Immunotherapy Platform Industry Restraints Table 5. Global Cell Immunotherapy Platform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cell Immunotherapy Platform Revenue Share by Company (2021-2026) Table 7. Global Cell Immunotherapy Platform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cell Immunotherapy Platform Key Company Manufacturing Base & Headquarters Table 9. Global Cell Immunotherapy Platform Company, Product Type & Application Table 10. Global Cell Immunotherapy Platform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cell Immunotherapy Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Autologous Immune Cell Therapy Table 15. Significant Companies of Allogeneic Immune Cell Therapy Table 16. Global Cell Immunotherapy Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cell Immunotherapy Platform Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cell Immunotherapy Platform Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cell Immunotherapy Platform Sales Value Share by Type (2021-2026) Table 20. Global Cell Immunotherapy Platform Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunotherapy Industry Table 22. Significant Companies of Biopharmaceutical Industry Table 23. Significant Companies of Others Table 24. Global Cell Immunotherapy Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cell Immunotherapy Platform Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Cell Immunotherapy Platform Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Cell Immunotherapy Platform Sales Value Share by Application (2021-2026) Table 28. Global Cell Immunotherapy Platform Sales Value Share by Application (2027-2032) Table 29. Global Cell Immunotherapy Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cell Immunotherapy Platform Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Cell Immunotherapy Platform Sales Value Share by Region (2021-2026) Table 32. Global Cell Immunotherapy Platform Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Cell Immunotherapy Platform Sales Value Share by Region (2027-2032) Table 34. Global Cell Immunotherapy Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cell Immunotherapy Platform Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Cell Immunotherapy Platform Sales Value Market Share by Country (2021-2026) Table 37. Global Cell Immunotherapy Platform Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Cell Immunotherapy Platform Sales Value Market Share by Country (2027-2032) Table 39. Kite Pharma Company Information Table 40. Kite Pharma Business Overview Table 41. Kite Pharma Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Kite Pharma Cell Immunotherapy Platform Product Portfolio Table 43. Kite Pharma Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis Cell Immunotherapy Platform Product Portfolio Table 48. Novartis Recent Development Table 49. Bristol Myers Squibb Company Information Table 50. Bristol Myers Squibb Business Overview Table 51. Bristol Myers Squibb Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bristol Myers Squibb Cell Immunotherapy Platform Product Portfolio Table 53. Bristol Myers Squibb Recent Development Table 54. Gilead Sciences Company Information Table 55. Gilead Sciences Business Overview Table 56. Gilead Sciences Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Gilead Sciences Cell Immunotherapy Platform Product Portfolio Table 58. Gilead Sciences Recent Development Table 59. Bluebird Bio Company Information Table 60. Bluebird Bio Business Overview Table 61. Bluebird Bio Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Bluebird Bio Cell Immunotherapy Platform Product Portfolio Table 63. Bluebird Bio Recent Development Table 64. Celyad Oncology Company Information Table 65. Celyad Oncology Business Overview Table 66. Celyad Oncology Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Celyad Oncology Cell Immunotherapy Platform Product Portfolio Table 68. Celyad Oncology Recent Development Table 69. Autolus Therapeutics Company Information Table 70. Autolus Therapeutics Business Overview Table 71. Autolus Therapeutics Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Autolus Therapeutics Cell Immunotherapy Platform Product Portfolio Table 73. Autolus Therapeutics Recent Development Table 74. Legend Biotech Company Information Table 75. Legend Biotech Business Overview Table 76. Legend Biotech Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Legend Biotech Cell Immunotherapy Platform Product Portfolio Table 78. Legend Biotech Recent Development Table 79. Celltrion Company Information Table 80. Celltrion Business Overview Table 81. Celltrion Cell Immunotherapy Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Celltrion Cell Immunotherapy Platform Product Portfolio Table 83. Celltrion Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Cell Immunotherapy Platform Product Image Figure 2. Global Cell Immunotherapy Platform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell Immunotherapy Platform Market Size (2021-2032) & (US$ Million) Figure 4. Global Cell Immunotherapy Platform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Autologous Immune Cell Therapy Image Figure 8. Allogeneic Immune Cell Therapy Image Figure 9. Global Cell Immunotherapy Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cell Immunotherapy Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cell Immunotherapy Platform Sales Value Share by Type (2021-2032) Figure 12. Immunotherapy Industry Image Figure 13. Biopharmaceutical Industry Image Figure 14. Others Image Figure 15. Global Cell Immunotherapy Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cell Immunotherapy Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cell Immunotherapy Platform Sales Value Share by Application (2021-2032) Figure 18. Global Cell Immunotherapy Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Cell Immunotherapy Platform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Cell Immunotherapy Platform Sales Value (2021-2032) & (US$ Million) Figure 21. North America Cell Immunotherapy Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Cell Immunotherapy Platform Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Cell Immunotherapy Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Cell Immunotherapy Platform Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Cell Immunotherapy Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Cell Immunotherapy Platform Sales Value (2021-2032) & (US$ Million) Figure 27. South America Cell Immunotherapy Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Cell Immunotherapy Platform Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Cell Immunotherapy Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Autologous Immune Cell Therapy
  • Allogeneic Immune Cell Therapy
Applications
  • Immunotherapy Industry
  • Biopharmaceutical Industry
  • Others
Companies covered
  • Kite Pharma
  • Novartis
  • Bristol Myers Squibb
  • Gilead Sciences
  • Bluebird Bio
  • Celyad Oncology
  • Autolus Therapeutics
  • Legend Biotech
  • Celltrion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cell Immunotherapy Platform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cell Immunotherapy Platform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cell Immunotherapy Platform Market Dynamics
  1. 2.1 Cell Immunotherapy Platform Industry Trends
  2. 2.2 Cell Immunotherapy Platform Industry Drivers
  3. 2.3 Cell Immunotherapy Platform Industry Opportunities and Challenges
  4. 2.4 Cell Immunotherapy Platform Industry Restraints
3 Cell Immunotherapy Platform Market by Company
  1. 3.1 Global Cell Immunotherapy Platform Company Revenue Ranking in 2025
  2. 3.2 Global Cell Immunotherapy Platform Revenue by Company (2021-2026)
  3. 3.3 Global Cell Immunotherapy Platform Company Ranking (2024-2026)
  4. 3.4 Global Cell Immunotherapy Platform Company Manufacturing Base and Headquarters
  5. 3.5 Global Cell Immunotherapy Platform Company Product Type and Application
  6. 3.6 Global Cell Immunotherapy Platform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cell Immunotherapy Platform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cell Immunotherapy Platform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cell Immunotherapy Platform Market by Type
  1. 4.1 Cell Immunotherapy Platform Type Introduction
  2. 4.1.1 Autologous Immune Cell Therapy
  3. 4.1.2 Allogeneic Immune Cell Therapy
  4. 4.2 Global Cell Immunotherapy Platform Sales Value by Type
  5. 4.2.1 Global Cell Immunotherapy Platform Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cell Immunotherapy Platform Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cell Immunotherapy Platform Sales Value Share by Type (2021-2032)
5 Cell Immunotherapy Platform Market by Application
  1. 5.1 Cell Immunotherapy Platform Application Introduction
  2. 5.1.1 Immunotherapy Industry
  3. 5.1.2 Biopharmaceutical Industry
  4. 5.1.3 Others
  5. 5.2 Global Cell Immunotherapy Platform Sales Value by Application
  6. 5.2.1 Global Cell Immunotherapy Platform Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cell Immunotherapy Platform Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cell Immunotherapy Platform Sales Value Share by Application (2021-2032)
6 Cell Immunotherapy Platform Regional Value Analysis
  1. 6.1 Global Cell Immunotherapy Platform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cell Immunotherapy Platform Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cell Immunotherapy Platform Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cell Immunotherapy Platform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cell Immunotherapy Platform Sales Value (2021-2032)
  7. 6.3.2 North America Cell Immunotherapy Platform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cell Immunotherapy Platform Sales Value (2021-2032)
  10. 6.4.2 Europe Cell Immunotherapy Platform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cell Immunotherapy Platform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cell Immunotherapy Platform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cell Immunotherapy Platform Sales Value (2021-2032)
  16. 6.6.2 South America Cell Immunotherapy Platform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cell Immunotherapy Platform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cell Immunotherapy Platform Sales Value Share by Country, 2025 VS 2032
7 Cell Immunotherapy Platform Country-level Value Analysis
  1. 7.1 Global Cell Immunotherapy Platform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cell Immunotherapy Platform Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cell Immunotherapy Platform Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cell Immunotherapy Platform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cell Immunotherapy Platform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cell Immunotherapy Platform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cell Immunotherapy Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Kite Pharma
  2. 8.1.1 Kite Pharma Company Information
  3. 8.1.2 Kite Pharma Business Overview
  4. 8.1.3 Kite Pharma Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Kite Pharma Cell Immunotherapy Platform Product Portfolio
  6. 8.1.5 Kite Pharma Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Cell Immunotherapy Platform Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Bristol Myers Squibb
  14. 8.3.1 Bristol Myers Squibb Company Information
  15. 8.3.2 Bristol Myers Squibb Business Overview
  16. 8.3.3 Bristol Myers Squibb Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb Cell Immunotherapy Platform Product Portfolio
  18. 8.3.5 Bristol Myers Squibb Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Cell Immunotherapy Platform Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Bluebird Bio
  26. 8.5.1 Bluebird Bio Company Information
  27. 8.5.2 Bluebird Bio Business Overview
  28. 8.5.3 Bluebird Bio Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bluebird Bio Cell Immunotherapy Platform Product Portfolio
  30. 8.5.5 Bluebird Bio Recent Developments
  31. 8.6 Celyad Oncology
  32. 8.6.1 Celyad Oncology Company Information
  33. 8.6.2 Celyad Oncology Business Overview
  34. 8.6.3 Celyad Oncology Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celyad Oncology Cell Immunotherapy Platform Product Portfolio
  36. 8.6.5 Celyad Oncology Recent Developments
  37. 8.7 Autolus Therapeutics
  38. 8.7.1 Autolus Therapeutics Company Information
  39. 8.7.2 Autolus Therapeutics Business Overview
  40. 8.7.3 Autolus Therapeutics Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Autolus Therapeutics Cell Immunotherapy Platform Product Portfolio
  42. 8.7.5 Autolus Therapeutics Recent Developments
  43. 8.8 Legend Biotech
  44. 8.8.1 Legend Biotech Company Information
  45. 8.8.2 Legend Biotech Business Overview
  46. 8.8.3 Legend Biotech Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Legend Biotech Cell Immunotherapy Platform Product Portfolio
  48. 8.8.5 Legend Biotech Recent Developments
  49. 8.9 Celltrion
  50. 8.9.1 Celltrion Company Information
  51. 8.9.2 Celltrion Business Overview
  52. 8.9.3 Celltrion Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celltrion Cell Immunotherapy Platform Product Portfolio
  54. 8.9.5 Celltrion Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst